Please login to the form below

Not currently logged in

Chiesi's ultra-rare genetic disorder therapy wins European backing

Lamzede is set to become the first approved therapy for Alpha-Mannosidosis

ChiesiChiesi Group’s Lamzede (velmanase alfa) has been recommended for approval in Europe, putting it on course to become the first pharmacological therapy to reach the market for Alpha-Mannosidosis (AM).

The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) was issued under ‘exceptional circumstances’. This aims to grant access for extremely rare disorder treatment when traditional large-scale clinical studies are not feasible.

In Lamzede’s case it has been investigated in 33 patients, both adults and children, with AM, an ultra-rare, genetic lysosomal storage disorder caused by the absence or malfunction of the alpha-mannosidase enzyme.

Patients with this disorder can experience symptoms such as facial coarsening, intellectual disability, progressive motor function disturbances, hearing impairment and impaired speech.

Lamzede, which was acquired when the Italian group bought Zymenex in 2013, is administered weekly as intravenous infusions, and the medicine works by replacing the missing or malfunctioning enzyme.

It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar claimed Europe’s first stem cell therapy approval.

Paolo Chiesi, vice president and head of R&D for Chiesi Group, said: “The positive opinion is an important milestone for brining this therapeutic option to patients affected by AM Across Europe.”

Lamzede, which has been investigated in 33 patients, both adults and children, and the Italian group expects a licencing decision by the European Commission in the second quarter of 2018.

Article by
Gemma Jones

31st January 2018

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....